Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 107, Issue 3, Pages 571-573Publisher
SPRINGER
DOI: 10.1007/s11060-011-0780-5
Keywords
Stroke; Recombinant tissue plasminogen activator; TPA; Cancer; Malignancy; Neoplasm
Categories
Ask authors/readers for more resources
People with cancer may be at increased risk for stroke, especially of cardioembolic and large vessel origin. Some clinicians are reluctant to use recombinant tissue plasminogen activator (rTPA) in the cancer population due to safety concerns. We conducted a retrospective review of patients who received rTPA for acute stroke at an academic cancer center. We report six patients with cancer treated with rTPA at our institution, four of whom had early neurologic recovery. Only one of our six patients suffered minor bleeding as a complication of rTPA. Acute stroke in patients with cancer may be treated with rTPA, and active cancer should not be considered an absolute contraindication to rTPA use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available